The role of chromatin regulators in neurodevelopmental disorders

NIH RePORTER · NIH · R01 · $580,045 · view on reporter.nih.gov ↗

Abstract

Abstract We propose to investigate the role of the chromatin methyltransferase DOT1L in neuronal function and determine how its disruption leads to neurodevelopmental disorders (NDD). Although the genetic causes of NDDs are heterogeneous, a high proportion of causative mutations are within the genes that encode chromatin regulators. Chromatin is the complex of DNA and the histone proteins that organize the genome and control gene expression. Chromatin regulating enzymes deposit a wide range of posttranslational modifications on histones such as methylation, acetylation, and many others. Interestingly, recent advances have identified mutations in the histone methyltransferase DOT1L in NDD patients with intellectual disability and developmental delays. However, the mechanisms through which DOT1L functions in the brain remain largely unknown. DOT1L is the sole methyltransferase of histone 3 lysine 79 where it deposits methylation marks (H3K79me). Patient mutations are de novo, monoallelic, and cluster in the catalytic domain. Our preliminary data indicate that they likely act as loss-of-function mutations and decrease methylation of H3K79. In addition, we found that DOT1L and H3K79me increase during neuronal development and that DOT1L depletion affects transcription of critical neuronal synaptic genes. Together, this work suggests that DOT1L plays a critical role in neuronal development and function. We hypothesize that partial loss of DOT1L and H3K79me disrupt transcription leading to cognitive deficits and changes in neuronal maturation and synaptic gene expression. To test this, we will bring together biochemical studies, genome-wide sequencing, and new cell and mouse lines to generate a model of the patient disorder and define the function of H3K79me in neurons. Merging new systems with a wide range of approaches has the potential to define how DOT1L affects cognition. We will first employ a heterozygous Dot1l knockout mouse model to examine how partial loss of DOT1L affects chromatin, transcription, neurogenesis, neuronal maturation, and behavior to provide insights into the disorder. Next, we will focus on H3K79me using a new mutant embryonic stem cell line that allows us to specifically examine the effects of H3K79me in differentiated neurons without perturbing other functions of DOT1L. We will use this stem cell model to measure H3K79me genomic localization during neuronal development and determine how H3K79me loss affects transcription and neuronal differentiation. By merging these diverse approaches, we will expand our understanding of both an emerging disorder and the role and regulation of H3K79me in neurons. In addition, these experiments will contribute to the broader understanding of how epigenetic regulators play a role in brain function and how their disruption leads to neurodevelopmental disorders.

Key facts

NIH application ID
10981097
Project number
1R01NS134755-01A1
Recipient
UNIVERSITY OF PENNSYLVANIA
Principal Investigator
Erica Megan Korb
Activity code
R01
Funding institute
NIH
Fiscal year
2024
Award amount
$580,045
Award type
1
Project period
2024-08-01 → 2029-07-31